PCM
FLGT icon

Prelude Capital Management’s Fulgent Genetics FLGT Stock Holding History

Prelude Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
51,698
-4,611
-8% -$78.2K 0.08% 288
2026
Q1 		$895K Buy
56,309
+18,813
+50% +$408K 0.07% 335
2025
Q4 		$985K Sell
37,496
-31,697
-46% -$822K 0.07% 315
2025
Q3 		$1.56M Buy
69,193
+232
+0.3% +$4.78K 0.12% 213
2025
Q2 		$1.37M Sell
68,961
-14,850
-18% -$289K 0.13% 189
2025
Q1 		$1.42M Buy
83,811
+68,368
+443% +$1.16M 0.11% 215
2024
Q4 		$285K Buy
+15,443
New +$302K 0.02% 820
2020
Q2 		– Sell
-942
Closed -$10K – 2048
2020
Q1 		$10K Sell
942
-6,505
-87% -$90.6K ﹤0.01% 1130
2019
Q4 		$96K Sell
7,447
-5,185
-41% -$61.6K ﹤0.01% 1120
2019
Q3 		$131K Buy
+12,632
New +$120K 0.01% 865

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's FLGT Position: Q2 2026 in Review

Prelude Capital Management reduced its Fulgent Genetics (FLGT) stake by 8.2% in Q2 2026, selling an estimated $78.2K and leaving 51,698 shares worth $1.06M. The position accounts for 0.08% of the portfolio, ranked #288.

Prelude Capital Management first reported a position in FLGT in Q3 2019 and has held it in 10 quarters since. The position peaked at $1.56M in Q3 2025. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Prelude Capital Management held 51,698 shares of Fulgent Genetics worth $1.06M as of Q2 2026.
  • Prelude Capital Management sold 4,611 Fulgent Genetics shares in Q2 2026, an estimated $78.2K.
  • Fulgent Genetics made up 0.08% of Prelude Capital Management's portfolio in Q2 2026, its #288 holding.
  • Prelude Capital Management first reported a position in Fulgent Genetics in Q3 2019 and has held it in 10 quarters since.
  • Prelude Capital Management's Fulgent Genetics position peaked at $1.56M in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.